The $518 million acquisition, announced in July, is expected to close Oct. 29. The stockholders’ votes approved the issuance of shares of Biovenus Class A common stock to the stockholders of Misonix.
“The combination with Misonix creates significant value and provides a deeper global portfolio of pain treatments, restorative therapies and surgical solutions for patients,” Bioventus CEO Ken Reali said in an Oct. 26 news release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
